• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Should Strong Q3 Earnings Require Action From Arkema (ENXTPA:AKE) Investors?

    Simply Wall St·11/07/2026 04:38:48
    Listen to the news
    • Arkema reported third quarter 2026 sales of €2,364.2 million and net income of €58 million, with earnings per share from continuing operations higher than a year earlier, and confirmed its full year EBITDA guidance at constant FX.
    • The group paired this earnings update with new R&D investments, an expanded Shanghai research site and a validated 2050 net zero target, which together underline how Arkema is leaning on Specialty Materials and technology development despite a challenging market backdrop.
    • We will now explore how Arkema's resilient Q3 EBITDA performance could influence the existing investment narrative built around Specialty Materials.

    See how Arkema's resilient Q3 update compares with other materials groups by checking which stocks make the cut in our hand picked 212 resilient stocks with low risk scores.

    Arkema Investment Narrative Recap

    To hold Arkema, you need to believe the shift toward Specialty Materials, tight cost control and disciplined capex can offset sluggish demand in Europe and North America. The Q3 2026 print fits that story, with EBITDA up 7% and sales at €2,364.2 million. The key near term swing factor remains volumes in construction and industrial markets, which still face cautious customer behavior.

    The biggest operational risk is extended weakness in Performance Additives and any renewed pressure in acrylics spreads, given how exposed Intermediates remain. Q3 resilience and confirmed EBITDA guidance at constant FX help, but they do not remove that cyclical risk. For now, the earnings update looks supportive rather than transformative.

    The clearest operational tie in to this earnings update is Arkema’s €10 million investment in its Global Battery R&D Center of Excellence. That commitment sits directly on top of the Specialty Materials thesis, particularly in batteries, 3D printing and electronics where earlier projects are already contributing incremental EBITDA. It reinforces the idea that management is still leaning into higher value applications.

    For you as a shareholder, the question is execution. Battery and advanced materials R&D spend needs to translate into commercially relevant products that support volumes and margins while macro conditions stay soft in Europe and the U.S. If these projects scale as planned, they could help counter slower acrylics and Performance Additives, but operational delivery remains the real catalyst to watch.

    What The Arkema Forecasts Assume

    Arkema's narrative projects €9.6 billion revenue and €444.6 million earnings by 2029. This assumes 2.7% yearly revenue growth and an earnings increase of about €426.1 million from €18.5 million today.

    Uncover why Arkema's fair value indicates a 9% potential upside to its current price that could narrow quickly.

    ENXTPA:AKE 1-Year Stock Price Chart
    ENXTPA:AKE 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate Arkema storyline puts much more weight on cost cuts as a potential accelerator. The most optimistic analysts were pencilling in revenue of about €10.0b and earnings near €609.0 million by 2029 before this Q3 update. That is a far punchier earnings path. Use this Q3 news to test which narrative you find more convincing.

    Explore 3 other Arkema fair value estimates, including one that suggests there could be as much as 153% upside from the current price!

    Reach Your Own Conclusion

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking For More Investment Ideas Beyond Arkema?

    If Arkema's Q3 update has sharpened your interest in materials and industrials, you can use that momentum to widen your watchlist. The Simply Wall St Screener lets you scan the market using fundamentals rather than headlines, so you can quickly filter for balance sheet strength, income potential and quality at a glance.

    • If you care most about defense in tougher markets, start with a universe of companies that score well on financial resilience through our 212 resilient stocks with low risk scores.
    • If income is your priority, you can focus your research on businesses that currently offer higher yields and look more robust by screening for 232 dividend fortresses.
    • If you want to search for less followed stories with solid fundamentals, broaden your research using a curated pool of 588 high quality undiscovered gems.